Human Menopausal Gonadotropin PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
61489-71-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Gonadotropin preparationurinary human FSH/LH (menotrophin)
Mechanism of action
Provides follicle-stimulating hormone (FSH) and luteinising hormone (LH) activity. FSH stimulates ovarian follicular development and granulosa-cell function, while LH supports theca-cell androgen production and, with appropriate stimulation, ovulation; in men, gonadotropin activity supports spermatogenesis through Sertoli and Leydig cell signalling.
Indications / reported uses
Controlled ovarian stimulation for assisted reproductive technology and ovulation induction in women with anovulation or inadequate gonadotropin response.
Stimulation of spermatogenesis in selected men with hypogonadotropic hypogonadism, usually in combination with hCG.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Human Menopausal Gonadotropin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Human Menopausal Gonadotropin Permitted Daily Exposure (PDE) report (the Human Menopausal Gonadotropin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Human Menopausal Gonadotropin Occupational Exposure Limit (OEL) report (the Human Menopausal Gonadotropin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.